Influenza epidemic and the launch of generic products
By Kim, Jin-Gu | translator Choi HeeYoung
22.10.11 12:09:59
가나다라
0
Invalidating Permiflu Patent
Following last year's Chong Kun Dang, HKino.N, and JW Lifescience, 11 companies approved generic this year
Flu pandemic warning for the first time in 3 years
▲GC Pharma Peramiflu, JW Pharmaceutical Fluenpera, Chong Kun Dang Peraonce Product Photo (clockwise from top left)
The Peramiflu-based flu treatment market, which was monopolized by GC Pharma, will be reorganized into a system in which 15 companies compete during the flu season this winter. In particular, unlike the past two years, when the number of flu patients plunged due to the prolonged COVID-19, the competition in this market is expected to be very fierce, given that the flu is expected to spread significantly this winter.◆Peramiflu patent is released, the generic license is expanded
According to the pharmaceutical industry on the 11th, a total of 15 companies have been approved for flu treatment containing Permiflu until that day. This original product is GC Pharma's Peramiflu. GC Pharm
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)